In an HIV‑positive patient, when is extracorporeal membrane oxygenation (ECMO) indicated?

ECMO in HIV-Positive Patients

Direct Recommendation

ECMO should be offered to HIV-positive patients with severe ARDS when standard indications are met, particularly in newly diagnosed or well-controlled HIV patients who are young, without significant comorbidities, and have potentially reversible respiratory failure—HIV status alone should not exclude patients from ECMO therapy. 1, 2

---

Clinical Evidence Supporting ECMO Use in HIV

The evidence demonstrates excellent outcomes when ECMO is applied appropriately in HIV-positive patients:

• 93% of newly diagnosed HIV patients with ARDS successfully bridged to pulmonary recovery with ECMO, with very good overall outcomes 1
• 67% survival at 90 days in a UK cohort of HIV patients receiving ECMO for severe respiratory failure, including those with poor HIV control and high illness severity 2
• Three of five patients (60%) with AIDS and PJP-related ARDS survived to ECMO decannulation in combined case series 3

These outcomes are comparable to or exceed survival rates in non-HIV populations with severe ARDS, challenging the historical view of immunosuppression as a contraindication 1, 2.

---

Standard ECMO Initiation Criteria Apply

HIV-positive patients should be evaluated using the same physiologic thresholds as HIV-negative patients:

Fast-Entry (Immediate) Criteria

• PaO₂/FiO₂ < 70 mmHg for ≥3 hours despite FiO₂ >0.70 and optimal PEEP 4
• PaO₂ <55 mmHg despite maximal conventional rescue therapies 5, 4

Slow-Entry (Delayed) Criteria

• PaO₂/FiO₂ <80 mmHg for ≥3 hours or <100 mmHg for ≥6 hours 4
• Plateau pressure >28-30 cmH₂O for ≥6 hours despite lung-protective ventilation 5, 4
• **Arterial pH <7.20-7.25 for ≥6 hours** due to uncompensated hypercapnia (PaCO₂ >60 mmHg) 4

---

Pre-ECMO Optimization Requirements

Before initiating ECMO, ensure all conventional rescue therapies have been attempted:

• Early prone positioning (initiated within ≤48 hours of ARDS onset, maintained ≥12-16 hours daily) reduces mortality and must be tried first 6, 4
• Neuromuscular blockade with cisatracurium for ≤48 hours during severe ARDS improves outcomes 4
• Lung-protective ventilation with tidal volume 4-6 mL/kg ideal body weight and plateau pressure <30 cmH₂O 4
• Optimal PEEP titration (≥12 cmH₂O based on gas-exchange response) 4

---

Patient Selection Factors Favoring ECMO in HIV

Certain characteristics predict better outcomes and should guide selection:

Favorable Characteristics

• Newly diagnosed HIV (typically younger, fewer comorbidities, good rehabilitation potential) 1
• Early disease stage (critical illness <7 days duration with reversible condition) 5
• Potentially reversible etiology (e.g., PJP pneumonia, viral pneumonia, bacterial pneumonia) 1, 2, 7
• Young age without significant comorbidities 5, 1

Unfavorable Prognostic Factors

• Higher viral load at presentation correlates with mortality 1
• Lower Horovitz index (PaO₂/FiO₂) at baseline 1
• Antiretroviral therapy initiated before ECMO (possibly indicating longer disease duration) 1
• Development of sepsis during ECMO (all deceased patients in one series had sepsis) 1
• Prolonged mechanical ventilation >9.6 days before ECMO worsens outcomes 4

---

Timing Considerations

ECMO must be initiated within 7 days of respiratory failure onset for optimal outcomes; delay beyond 7-9 days of mechanical ventilation is associated with markedly worse survival 4, 1. This is particularly critical in HIV patients, where ECMO provides time for:

• Antimicrobial therapy to take effect 1
• Lung-protective ventilation to prevent further injury 1
• Immune system reconstitution with antiretroviral therapy 1

---

Special Consideration: Immune Reconstitution Inflammatory Syndrome (IRIS)

ECMO has proven effective even for ARDS caused by IRIS, a paradoxical worsening after initiating antiretroviral therapy:

• Successful ECMO treatment reported in IRIS-associated ARDS, including one patient requiring repeat ECMO with excellent outcome 3, 8
• IRIS typically occurs in newly diagnosed, ART-naïve patients starting therapy 3
• ECMO allows time for the exaggerated inflammatory response to resolve while protecting the lungs 8

---

Mode Selection: VV-ECMO vs VA-ECMO

Venovenous (VV) ECMO is preferred for isolated respiratory failure when cardiac function is adequate:

• VV-ECMO provides oxygenated blood back to the venous circulation and is appropriate when norepinephrine requirement ≤0.5 µg/kg/min and mean arterial pressure ≥65 mmHg 4
• VA-ECMO is indicated only for combined cardiopulmonary failure with severe cardiogenic shock (reduced LV ejection fraction, norepinephrine >0.5 µg/kg/min, right-ventricular overload with pulmonary artery systolic pressure >40 mmHg) 4

Most HIV patients with PJP or viral pneumonia have isolated respiratory failure and should receive VV-ECMO 1, 2, 7.

---

Institutional Requirements

ECMO should only be performed at high-volume centers treating >20-25 cases annually, as these centers demonstrate significantly better outcomes 4, 9:

• A 24/7 multidisciplinary ECMO team (physicians, nurses, perfusionists, ECMO specialists) is mandatory 4
• Mobile ECMO teams should be available for retrieval from referring hospitals 5, 4
• Hospitals without ECMO capability must establish formal pathways for rapid identification and transfer of eligible patients 4, 6

---

Monitoring During ECMO in HIV Patients

Standard ECMO monitoring applies, with particular attention to infection:

• Continuous arterial blood pressure and ECMO flow monitoring 4, 9
• Repeated echocardiography, especially for VA-ECMO, to detect left-ventricular overload 4, 9
• Daily fluid balance, central venous oxygen saturation (SvO₂), and lactate measurements 4
• Vigilant surveillance for sepsis, as all deceased HIV patients in one series developed sepsis during ECMO 1

---

Common Pitfalls to Avoid

• Excluding HIV patients from ECMO consideration based solely on HIV status—this is outdated practice not supported by current evidence 1, 2
• Delaying ECMO beyond 7 days of mechanical ventilation—early initiation is critical for survival 4, 1
• Failing to optimize conventional therapies first (prone positioning, neuromuscular blockade, lung-protective ventilation) 4, 6
• Transferring patients too late—deterioration is rapid in some etiologies; establish transfer protocols early 5
• Assuming all immunocompromised states have equally poor prognosis—newly diagnosed HIV patients have excellent rehabilitation potential 1

---

Evidence Quality and Limitations

The recommendation to offer ECMO to HIV patients is based on:

• High-quality observational data showing 67-93% survival in selected HIV patients 1, 2
• General ECMO guidelines that provide conditional recommendations with low-to-moderate certainty of evidence for severe ARDS 4
• No randomized trials specifically in HIV populations, but outcomes match or exceed those in general ARDS populations 1, 2

The evidence consistently demonstrates that HIV status alone should not be a contraindication to ECMO, particularly in newly diagnosed patients with reversible respiratory failure 1, 2, 7.